Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference
Benitec Biopharma (NASDAQ: BNTC), a clinical-stage biotechnology company focused on gene therapy and developing genetic medicines using their proprietary 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform, has announced their participation in the Guggenheim Securities Healthcare Conference. CEO Jerel A. Banks, M.D., Ph.D., will present at the conference on November 11, 2024, at 2:30 PM in Boston. The presentation will be conducted in a fireside chat format with opportunities for one-on-one meetings, and will be available via live webcast.
Benitec Biopharma (NASDAQ: BNTC), una compagnia biotecnologica in fase clinica focalizzata sulla terapia genica e lo sviluppo di farmaci genetici utilizzando la loro piattaforma proprietaria di 'Silence and Replace' per l'interferenza RNA diretta da DNA (ddRNAi), ha annunciato la sua partecipazione alla Guggenheim Securities Healthcare Conference. Il CEO Jerel A. Banks, M.D., Ph.D., presenterà alla conferenza il 11 novembre 2024, alle 14:30 a Boston. La presentazione sarà condotta in formato di conversazione informale con opportunità per incontri individuali e sarà disponibile tramite webcast in diretta.
Benitec Biopharma (NASDAQ: BNTC), una compañía de biotecnología en etapa clínica enfocada en la terapia génica y el desarrollo de medicamentos genéticos utilizando su plataforma propietaria de 'Silence and Replace' para la interferencia de ARN dirigida por ADN (ddRNAi), ha anunciado su participación en la Guggenheim Securities Healthcare Conference. El CEO Jerel A. Banks, M.D., Ph.D., presentará en la conferencia el 11 de noviembre de 2024, a las 14:30 en Boston. La presentación se llevará a cabo en un formato de charla informal con oportunidades para reuniones individuales, y estará disponible a través de transmisión en vivo.
Benitec Biopharma (NASDAQ: BNTC)는 유전자 치료에 초점을 맞추고 'Silence and Replace' DNA 유도 RNA 간섭(ddRNAi) 플랫폼을 사용하여 유전 약물을 개발하는 임상 단계의 생명공학 회사로, 구겐하임 증권 헬스케어 컨퍼런스에 참여한다고 발표했습니다. CEO Jerel A. Banks, M.D., Ph.D.는 2024년 11월 11일, 오후 2시 30분에 보스턴에서 컨퍼런스에서 발표할 예정입니다. 발표는 편안한 대화 형식으로 진행되며, 개별 회의 기회가 제공되고, 라이브 웹캐스트를 통해 제공될 것입니다.
Benitec Biopharma (NASDAQ: BNTC), une entreprise de biotechnologie en phase clinique axée sur la thérapie génique et le développement de médicaments génétiques utilisant leur plateforme propriétaire 'Silence and Replace' pour l'interférence ARN dirigée par ADN (ddRNAi), a annoncé sa participation à la Guggenheim Securities Healthcare Conference. Le PDG Jerel A. Banks, M.D., Ph.D., présentera lors de la conférence le 11 novembre 2024 à 14h30 à Boston. La présentation se fera sous forme de discussion informelle avec des opportunités pour des réunions individuelles et sera disponible en direct via un webinaire.
Benitec Biopharma (NASDAQ: BNTC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Gentherapie und die Entwicklung genetischer Medikamente mithilfe ihrer proprietären 'Silence and Replace'-Plattform für DNA-gesteuerte RNA-Interferenz (ddRNAi) konzentriert, hat seine Teilnahme an der Guggenheim Securities Healthcare Conference bekannt gegeben. CEO Jerel A. Banks, M.D., Ph.D., wird am 11. November 2024 um 14:30 Uhr in Boston auf der Konferenz präsentieren. Die Präsentation wird im Format eines Kamin-Gesprächs durchgeführt, mit Möglichkeiten für Einzelgespräche, und wird über einen Live-Webcast verfügbar sein.
- None.
- None.
HAYWARD, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announces CEO Jerel A. Banks, M.D., Ph.D. will be participating in the Guggenheim Securities Healthcare Conference, taking place in Boston from November 11-13, 2024.
Date: November 11, 2024
Time: 2:30 PM
Format: Fireside Chat & 1x1 Meetings
The Benitec presentation will also be available via live webcast here.
Please contact your Guggenheim representative to schedule a 1x1 meeting with Benitec management.
About Benitec Biopharma Inc.
Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at www.benitec.com.
Investor Relations Contact:
Irina Koffler
LifeSci Advisors
Tel: (917) 734-7387
ikoffler@lifesciadvisors.com
FAQ
When is Benitec Biopharma (BNTC) presenting at the Guggenheim Securities Healthcare Conference 2024?
What type of presentation format will BNTC use at the Guggenheim Healthcare Conference?
Will there be a webcast of Benitec's (BNTC) Guggenheim Conference presentation?
What is Benitec Biopharma's (BNTC) main technology platform?
